Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) is expected to post its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Lucid Diagnostics to post earnings of ($0.15) per share and revenue of $1.42 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Lucid Diagnostics Price Performance
LUCD stock opened at $1.39 on Monday. The business has a fifty day moving average price of $1.14 and a 200 day moving average price of $0.96. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.63. The stock has a market capitalization of $82.49 million, a price-to-earnings ratio of -1.22 and a beta of 1.34.
Analyst Upgrades and Downgrades
Separately, Ascendiant Capital Markets dropped their price target on Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating for the company in a report on Monday, December 9th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Lucid Diagnostics presently has an average rating of “Buy” and a consensus price target of $3.63.
Lucid Diagnostics Company Profile
Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
See Also
- Five stocks we like better than Lucid Diagnostics
- EV Stocks and How to Profit from Them
- How to Build the Ultimate Everything ETF Portfolio
- How to Invest in Blue Chip Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- How to Calculate Return on Investment (ROI)
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.